781 related articles for article (PubMed ID: 26361647)
1. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
2. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
4. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
8. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
9. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
10. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
11. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
12. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
Jiang N; Qi C; Trieu Y; Reece D; Chang H
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Kurahashi S; Suzuki K; Sawamoto A; Adachi T; Iwasaki T; Suzuki H; Sugimoto T; Narimatsu H; Hayakawa F; Sugiura I
Rinsho Ketsueki; 2010 Mar; 51(3):174-80. PubMed ID: 20379111
[TBL] [Abstract][Full Text] [Related]
14. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
15. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
[TBL] [Abstract][Full Text] [Related]
16. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
[TBL] [Abstract][Full Text] [Related]
17. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
19. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]